Endocrinology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 The human endocrine system comprises of a number of glands such as pituitary, thyroid, parathyroid, pancreas, pineal, thymus, parathyroid and gonads. These glands secrete hormones into the blood which are responsible for metabolism, growth, sexual development and other body functions. Endocrinology drugs are used to treat diseases related with insufficient hormones supply and dysfunctional glands. Various diseases related with endocrine system are Addison’s diseases, Cushing’s syndrome, Diabetes, Goiter, acromegaly, gigantism, osteomalacia, hypertension, hyperlipidemia, polycystic ovary syndrome (PCOS) and thyroiditis. Browse Full Report: http://www.transparencymarketresearch.com/endocrinology-drugs-market.html The global market for endocrinology drugs are divided into segments such as diabetes market, growth hormone market, acromegaly market and hypogonadism market. The market for diabetes is experiencing tremendous growth under the influence of increasing prevalence of diabetes worldwide. It is expected that by 2025, India and China will rank as the top most diabetic populated countries. Inception of new drug delivery for growth hormone and rising cases of cancers, end stage renal disease (ESRD) and increasing disposable income are driving the market for human growth hormone. On the other hand off label uses of human growth hormone (HGH) for body building, anti-aging and in sports are posing a challenge to the society not only because it is illegal but also because use of HGH is associated with high risk and side effects. Hypogonadism market comprises of testosterone, estrogen and progesterone replacement therapy market. This segment will experience the growth due to increasing awareness about post menopausal hazards amongst women, awareness about testosterone amongst men. Recent years have witnessed many advances in the treatment of endocrine diseases such as introduction of new drugs and novel drug delivery methods. Recently FDA approved endocrinology drugs include Invokana (canagliflozin) of Janssen Pharmaceuticas for the treatment of diabetes mellitus II, Osphena (ospemifene) of Shiongi for the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause. Others include Brisdelle (low-dose paroxetine mesylate), Nesina (alogliptin), Belviq (lorcaserin hydrochloride) and Cometriq